Repotrectinib
ATC L01EX28 · 6 markets · 12 records
AU 5 records · 3 strengths
- 40 mgcapsuleAugtyroAUGTYRO repotrectinib 40 mg capsule bottle
- 160 mgcapsuleAugtyroAUGTYRO repotrectinib 160 mg capsule blister pack
Records without a stated strength · 1 Augtyro
US 2 records · 2 strengths
TW 1 records · 1 strengths
- 40 mgcapsuleAugtyro歐格樂膠囊40毫克
HK 1 records · 1 strengths
Records without a stated strength · 1 Augtyro
EU 1 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Records without a stated strength · 1 Augtyro
| Strength / form / release | US | AU | TW | HK | EU |
|---|---|---|---|---|---|
| 40 mg capsule | Augtyro | Augtyro AUGTYRO repotrectinib 40 mg capsule bottle | Augtyro 歐格樂膠囊40毫克 | ||
| 160 mg capsule | Augtyro | Augtyro AUGTYRO repotrectinib 160 mg capsule blister pack | |||
unknown | Augtyro | Augtyro | Augtyro |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.